624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma

Alison J. Moskowitz, Gunjan Shah, Heiko Schöder, et al.

Authors Conclusion from the Abstract: Second-line therapy with pembrolizumab-GVD is a highly effective and well-tolerated regimen that can efficiently bridge pts with RR cHL to HDT/AHCT. Updated results including all 39 enrolled pts will be presented at the meeting. Given the high CR rate observed with pembrolizumab-GVD, an expansion cohort evaluating 8 cycles of pembrolizumab maintenance (instead of HDT/AHCT) for patients who achieve CR after 4 cycles of pembrolizumab-GVD is planned.

Christopher A. Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, et al.

Authors Conclusion from the Abstract: Older patients with cHL and multiple comorbidities have very high response rates and a clinically meaningful improvement in PFS with BV as monotherapy or combined with other single agents and improved tolerability versus combination chemotherapy. Median overall survival exceeded 6 yrs with BV monotherapy. BV+nivo or BV+DTIC appeared to be the most reasonable combination treatment options in this study.

Alex F. Herrera, Lu Chen, Yago Nieto, et al.

Authors Conclusion from the Abstract: Post-HCT consolidation with BV-Nivo in pts with high-risk RR HL is a promising approach, with only 1 relapse observed in our cohort with short follow-up thus far. Post-HCT BV-Nivo was tolerable, though IrAEs were observed more frequently than in the pre-HCT setting and PN and neutropenia were common.

Jakub Svoboda, Stefan K. Barta, Daniel J. Landsburg, et al.

Authors Conclusion from the Abstract: The combination of everolimus and itacitinib is feasible and its efficacy compares favorably to historical reports for everolimus or JAK inhibitor monotherapy in r/r cHL. Our results suggest that the rational design for targeting multiple pathways can improve therapeutic outcomes in r/r cHL and warrants further investigation, particularly in pts with disease refractory to BV and PD-1i. Attempts to determine predictive biological markers of efficacy in long-term responders are ongoing.

Alex F. Herrera, Carmelo Carlo-Stella, Graham P. Collins, et al.

Authors Conclusion from the Abstract: Current data show that therapy with Cami has encouraging anti-tumor activity in heavily pretreated pts with R/R cHL. Safety was consistent with that reported at Ph 1, with no new safety concerns identified and similar incidence of GBS/polyradiculopathy. Following a positive risk-benefit assessment, the enrollment pause was lifted, and pts continue to be enrolled. Updated efficacy and safety results will be presented at the meeting.

Olivier Casasnovas, Judith Racape, Julie Dechene, et al. 

Authors Conclusion from the Abstract: The prolonged follow-up confirms that the PET-driven strategy delivering 4 cycles of ABVD in PET negative patients after 2 cycles of BEA is non inferior compared to standard 6 cycles of BEA. PET4 provides additionnal prognostic information to PET2 and identifies patients with particularly poor prognosis. The PET-driven treatment allows to reduce significantly the risk of infertility in both men (recovery of oligospermia) and women (decreasing by 5 the risk of POI) and improves the chances of spontaneous pregnancy after completion of HL treatment. With the current follow-up the risk of SPM was low (2.7%) and similar in both arms.